Gan&Lee Pharmaceuticals Shandong Co., Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation empagliflozin tablets (specification: 10 mg, produced by Huayi Pharmaceutical Technology (Anhui) Co., Ltd. and provided by Ganli Pharmaceutical Shandong Co., Ltd.) and the reference preparation empagliflozin tablets (Otangjing®, specification: 10 mg; produced by Boehringer Ingelheim International GmbH & Co. KG) in healthy subjects after a single dose in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. The secondary purpose of the study is to evaluate the safety of the test preparation empagliflozin tablets (specification: 10 mg) and the reference preparation empagliflozin tablets (Otangjing®, specification: 10 mg) in healthy subjects.

Part A aims to evaluate the safety, tolerability and relative bioavailability of single-dose GZR18 tablets. Part B aims to evaluate the safety, tolerability and relative bioavailability of multiple continuous doses of GZR18 tablets. Part C aims to evaluate the effect of meal time on the pharmacokinetic parameters of GZR18 tablets.

The main purpose of the study is to study the pharmacokinetics of the test preparation Sitagliptin Metformin Tablets (II) (Specification: 50 mg/850 mg, produced by Ganli Pharmaceutical Shandong Co., Ltd.) and the reference preparation Sitagliptin Metformin Tablets (II) (Janoda®, Specification: 50 mg/850 mg, produced by Patheon Puerto Rico, Inc. (Manati)) in healthy subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary purpose of the study is to evaluate the safety of the test preparation Sitagliptin Metformin Tablets (II) (Specification: 50 mg/850 mg) and the reference preparation Sitagliptin Metformin Tablets (II) (Janoda®, Specification: 50 mg/850 mg) in healthy subjects.